Every SEC Form 3/4/5 on record for this filer (CIK 1126490) — 4 issuers, 207 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | Director | 2016-05-18 → 2026-05-29 | 27 | −$13M |
| ALKS | Alkermes plc. | Director and CEO, Alkermes plc | 2015-09-10 → 2026-03-04 | 73 | −$79M |
| EPZM | Epizyme, Inc. | Director · lapsed | 2015-07-10 → 2020-06-02 | 6 | — |
| XLRN | ACCELERON PHARMA INC | Director · lapsed | 2016-03-07 → 2019-01-29 | 5 | −$2M |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| NBIX | 2026-05-15 | Sell | 15,000 | $157.65 | $2M | 34,480 |
| NBIX | 2024-05-17 | Sell | 2,100 | $141.84 | $297,864 | 31,611 |
2 of 4 issuers are covered and open a security page; the rest are on file here only.